Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Symptomatic Carotid Outcomes Registry
NCT05300737
Recruiting
The purpose of this study is to build upon trials done over 30 years ago, which did not include statins, new antiplatelet agents, and newer antihypertensive medications. Since the landmark trials (NASCET, ECST), there have been new developments in medical stroke prevention, which creates a gap in knowledge. The aim of this study is to evaluate that clinical care with Intensive Medical Therapy (IMT) alone, the one year stroke rate in patients with symptomatic carotid stenosis and low risk clinica... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/02/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
Register for Updates
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
NCT04365374
Recruiting
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Piedmont Hospital, Atlanta, Georgia
Conditions: Brain Metastases
Register for Updates
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
NCT04310020
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Augusta University Medical Center, Augusta, Georgia
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
Register for Updates
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
NCT07042516
Recruiting
This Randomized Clinical Trial entitled Safety and Efficacy of a Peripherally Restricted Selective Kappa Agonist for Moderate to Severe Menopausal Symptoms in Midlife Women is a Phase 2a randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of asimadoline TP0052 for the treatment of moderate to severe menopausal vasomotor symptoms (VMS). The design includes: 2 weeks of daily recording of VMS prior to drug treatment; 8 weeks of double-blind treatment with the perip... Read More
Gender:
FEMALE
Ages:
Between 40 years and 62 years
Trial Updated:
07/01/2025
Locations: Department of Gynecology & Obstetrics, Emory University School of Medicine, Atlanta, Georgia
Conditions: Vasomotor Symptoms
Register for Updates
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
NCT07010159
Recruiting
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/01/2025
Locations: Investigational Site 001, Columbus, Georgia
Conditions: Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Register for Updates
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Balanced Life Health Care Solutions/SKYCRNG, Lawrenceville, Georgia
Conditions: Type 2 Diabetes
Register for Updates
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518
Recruiting
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease pro... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/01/2025
Locations: Nephronet Clinical, Buford, Georgia
Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Register for Updates
Amplitude Vascular Systems (AVS) Lithotripsy POWER PAD 2 Trial
NCT06457685
Recruiting
POWER PAD 2 is a prospective, single-arm, multicenter, non-randomized clinical study designed to demonstrate the safety and effectiveness of the Amplitude Vascular Systems (AVS) Pulse Intravascular Lithotripsy™ (Pulse IVL™) System for treatment of calcified (moderate to severe), stenotic, superficial femoral and popliteal arteries in patients with peripheral arterial disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Piedmont Heart Institute, Atlanta, Georgia
Conditions: Peripheral Arterial Disease (PAD)
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Atlanta, Georgia
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
NCT05396833
Recruiting
This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Augusta University - formerly Georgia Regents University, Augusta, Georgia
Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Register for Updates
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
NCT04928677
Recruiting
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3. The researchers also want to study the way codrituzumab is absorbed, distributed, and cleared from the body.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/01/2025
Locations: Children's Healthcare of Atlanta (Data Collection Only), Atlanta, Georgia
Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
NCT04862468
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for up to 14 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/01/2025
Locations: Piedmont Heart Institute, Atlanta, Georgia
Conditions: Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Register for Updates